Product Images Sildenafil Citrate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Sildenafil Citrate NDC 50436-0185 by Unit Dose Services, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

2 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 01

2 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 01

1 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 02

1 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 02

7 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 03

7 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 03

This appears to be a chart or table showing the interactions between different drugs and their effect on the AUC and cmax values. It also provides recommendations on whether a dose adjustment is necessary or not. There is a mention of a clinical study regarding the combination of sildenafil and bosentan therapy and their impact on exercise capacity.*

8 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 04

8 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 04

This text appears to be a list of drugs and their effect on INR AUC and Cmax values, along with their recommended dose adjustment when interacting with other drugs. There is also a note on the effect of flonavr on sildenafil PK and a statement on the lack of benefit on exercise capacity when sidonati is added to bosantan therapy, based on clinical studies.*

4 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 05

4 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 05

This text represents a table showing changes from a baseline (in meters) at weeks 4, 8, and 12 for different dosages of Sildenafil and Placebo during a study. Sildenafil was administered in 20mg TID, 40mg TID, and 80mg TID dosages, and the key denotes the different dosages. No additional information is provided.*

5 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 06

5 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 06

This is a medical document focusing on the treatment and evaluation of patients with idiopathic pulmonary arterial hypertension (PAH). The text includes some patient data, such as age, gender, and mean pulmonary artery pressure readings. The treatment approach discussed in the document involves using sildenafil 20 mg three times daily alongside a placebo. The document also mentions "PH criteria" related to functional capacity. Finally, there is a graph of the placebo-corrected change in six-minute walk distance.*

1 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 07

1 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 07

Figure 12 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 08

Figure 12 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 08

The Figure 12 shows the mean change from baseline in the distance walked in six minutes by the ITT population in a study with Sildenafil Protocol A1481244. The graph represents the mean change from baseline and the Standard Error for each treatment at each visit up to week 12. The X-axis shows the week of the study, and the Y-axis indicates the change from baseline in meters. Three different doses of Sildenafil, 1mg TID, 5mg TID, and 20mg TID have been used.*

9 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 09

9 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 09

9 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 10

9 - 55aa9711 6df5 4516 bf00 a1acf7f7a464 10

Label Image - lbl504360185

Label Image - lbl504360185

This is a medication label for Sildenafil with a strength of 20mg and National Drug Code (NDC) of 50436.0185-1. However, the rest of the text is not legible due to errors.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.